Skip to main content

Table 1 Patient characteristic and positive biopsy rate by different biopsy approach and PSA level

From: Surface-projection-based transperineal cognitive fusion targeted biopsy of the prostate: an original technique with a good cancer detection rate

 

SB only

SB + TB

p

All

N

47

79

 

126

Age

66.9 ± 8.7

69.7 ± 9.3

0.09

68.7 ± 9.2

PSA

11.5 (5.2–16.3)

13.0 (6.7–33.6)

0.07

11.8 (6.5–25.2)

Volume

72.1 ± 64.1

53.6 ± 38.2

0.045

60.5 ± 50.0

PCa

5 (10.6%)

56 (70.9%)

<0.001

61 (48.4%)

csPC

2 (4.3%)

52 (65.8%)

<0.001

54 (42.9%)

PSA (pos./tot)

 <10

2/21 (9.5%)

17/31 (54.8%)

0.001

19/52 (36.5%)

 10–20

3/17 (17.6%)

11/16 (68.8%)

0.005

14/33 (42.4%)

 20–50

0/8 (0%)

12/16 (75.0%)

<0.001

12/24 (50.0%)

 >50

0/1 (0%)

16/16 (100%)

0.006

16/17 (94.1%)

Bone meta

1/5 (20%)

19/56 (33.9%)

0.51

20/61 (32.8%)

  1. SB: systematic biopsy; TB: targeted biopsy; csPC:clinically significant prostate cancer; pos.:positive; tot.: total; meta: metastasis